Grand Rounds – Genetics, Signaling, and Academic Discovery as Gateways to Drug Development | Paul Yu, MD PhD | Sept 14, 2022
Dr. Paul Yu is Director of the Cardiovascular Research Center (CVRC) at Massachusetts General Hospital. In this Grand Rounds he will speak about his ALK2 small molecule innovations through IPO – spanning from discovery, non-dilutive sources of funding for medicinal chemistry and proof of concept, to licensing to the newco he cofounded as Keros Therapeutics Inc (NASDAQ:KROS) as well as Phase 1 and 2 trials. He will additionally speak candidly about the decision-making and efforts that impacted the development of IP, value, and inflection points in his successful venture.
Dr. Paul Yu is recipient of the Charles Addison Sanders and Elizabeth Ann Sanders Endowed Chair, Associate Professor of Medicine at Harvard Medical School, and Physician in Cardiovascular Medicine at Massachusetts General Hospital (MGH). Dr. Yu completed his AB in Philosophy and a BS in Biological Sciences at Stanford University, MD and PhD (Immunology) degrees at Duke University, completed Internal Medicine residency at UCSF, clinical and research fellowships in Cardiovascular Disease at MGH, and is board certified in Cardiovascular Medicine. Following a postdoctoral fellowship in cardiovascular biology with Dr. Kenneth Bloch, Dr. Yu established his independent laboratory at MGH in 2007, joined a collaborative basic and translational research effort in pulmonary arterial hypertension at BWH in 2011, and has returned to MGH in 2022 as Director of the CVRC.
Learn More: www.innovationmeshnetwork.org / innovation.massgeneralbrigham.org
Chief Innovation Officer: Chris Coburn
Grand Rounds Director: Marc Succi, MD